anti-CD19/CD22 CAR-T cells
Sponsors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Conditions
Acute Lymphoblastic LeukemiaCD19-positive ALLMRD-positive
Phase 1
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
CompletedNCT03919526
Start: 2019-08-11End: 2023-11-01Updated: 2023-12-08
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL
NCT04303520
Start: 2018-05-03End: 2021-02-28Target: 20Updated: 2020-03-11